Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome

Deborah A. Hall, Elizabeth Berry-Kravis, Randi J. Hagerman, Paul J. Hagerman, Cathlin D. Rice, Maureen A. Leehey

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


There is no established treatment for the neurological features of the recently discovered fragile X-associated tremor/ataxia syndrome (FXTAS). Fifty-six patients with FX-TAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 11 subjects with defirdte FXTAS, 8 (70%) were on medications for their neurological symptoms, whereas most subjects with possible or probable FXTAS, 31 (70%) of 45 subjects, were not on medications. Although no therapy was uniformly effective for intention tremor, ataxia, Parkinsonism, memory loss, or anxiety, some subjects with intention tremor or Parkinsonism reported improvement with medications frequently used in other movement disorders. Overall., all 22 subjects on medications reported improvement in one or more symptoms. Lack of insight, recall bias, and cognitive impairment may have resulted in an underestimation of the beneficial effect of medical therapy. This study suggests that patients with FX-TAS can derive improvement from medication treatment for some of their symptoms.

Original languageEnglish (US)
Pages (from-to)1741-1744
Number of pages4
JournalMovement Disorders
Issue number10
StatePublished - Oct 2006


  • Ataxia
  • Fragile X
  • Medications
  • Tremor

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome'. Together they form a unique fingerprint.

Cite this